Target-oriented therapy: Emerging drugs for atopic dermatitis
@article{Lauffer2016TargetorientedTE, title={Target-oriented therapy: Emerging drugs for atopic dermatitis}, author={Felix Lauffer and Johannes Ring}, journal={Expert Opinion on Emerging Drugs}, year={2016}, volume={21}, pages={81 - 89} }
ABSTRACT Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a life-time prevalence of 10 – 20% in western countries. Patients suffer from stigmatizing eczematous skin lesions, persisting itch and sleep disorders. Starting usually in early childhood the course of AD is heterogeneous. While most frequently AD disappears before adolescence, about 30% of patients show a chronic persisting course. There is an urgent need for new therapeutic options as until now…
32 Citations
Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
- BiologyDrug design, development and therapy
- 2017
Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of bothIL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD.
Atopic dermatitis : emerging therapies Two identically designed phase III clinical trials
- Medicine
- 2018
Novel topical and systemic therapies for the safe and effective long-term management of AD are greatly needed as well as novel early life approaches to preventing the disease onset.
Systemic Treatment of Adult Atopic Dermatitis: A Review
- Medicine, BiologyDermatology and Therapy
- 2016
This review focuses on the use of systemic treatments in adult AD patients analyzing published literature and indicates that standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries.
Current and emerging topical therapies for atopic dermatitis.
- Biology, MedicineClinics in dermatology
- 2017
Molecular signatures order the potency of topically applied anti‐inflammatory drugs in patients with atopic dermatitis
- Medicine, BiologyThe Journal of allergy and clinical immunology
- 2017
The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
- Medicine, BiologyInflammation and regeneration
- 2017
The etiopathogenesis of the disease is summarized and a rationale for choosing the novel targeted therapy that will be available in the future is provided.
The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis
- Biology, MedicineImmunological reviews
- 2017
This review summarizes the etiopathogenesis of AD and provides the rationale for selecting a novel targeted therapy, Dupilumab, which has recently been developed for AD treatment.
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
- Biology, MedicineExpert review of clinical immunology
- 2021
The IL-4, IL-13, and IL-31 inflammatory pathways have been identified as hallmark features in the pathogenesis of the disease, contributing uniquely and synergistically to immune and barrier abnormalities as well as the key symptoms, such as pruritis.
Pathophysiology, Diagnosis, and Management of Infections in Atopic Dermatitis
- Medicine, BiologyCurrent Dermatology Reports
- 2019
Assessment of recent changes in the understanding of pathophysiology, diagnosis, and management of infections in Atopic dermatitis finds that more targeted therapies and skin probiotics may address inflammation and S. aureus in the prevention of infection in AD.
References
SHOWING 1-10 OF 89 REFERENCES
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
- MedicineJournal of the European Academy of Dermatology and Venereology : JEADV
- 2012
The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and Evaluation. The consensus process consisted…
Immunology of atopic eczema: overcoming the Th1/Th2 paradigm
- Medicine, BiologyAllergy
- 2013
Current understanding of immune as well as barrier abnormalities into the pathogenesis mosaic of AE are pieces together.
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
- MedicineThe New England journal of medicine
- 2014
Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
- Medicine, BiologyThe Journal of allergy and clinical immunology
- 2014
Treatment of severe refractory adult atopic dermatitis with ustekinumab
- MedicineInternational journal of dermatology
- 2012
A 21-year-old Caucasian woman presented in March 2003 with a longstanding history of atopic dermatitis (AD) in addition to allergic contact dermatitis that emerged in response to paraphenylenediamine and had been diagnosed one year earlier.
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab.
- Medicine, BiologyActa dermato-venereologica
- 2016
An improvement in AD was observed during the treatment period, with aggravation during follow-up, and further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE Levels.
Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients.
- MedicineActas dermo-sifiliograficas
- 2014
Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy
- MedicineThe British journal of dermatology
- 1995
It is suggested that CyA treatment may improve the long‐term outcome of atopic dermatitis, although most patients initially relapsed a few weeks after CyA was stopped, although all disease parameters showed improvement when these patients were seen 1 year after the study.
Characterization of different courses of atopic dermatitis in adolescent and adult patients
- BiologyAllergy
- 2013
The aim of this study was to classify different courses of AD and to correlate these with specific risk factors for severe variants of AD.
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
- MedicineArchives of dermatology
- 2012
Gene ontologic analyses comparing baseline with samples during treatment revealed alterations in immune response pathways, especially those related to cyclic adenosine monophosphate–mediated signaling, which support further development of apremilast for treatment of atopic dermatitis.